These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25545358)

  • 1. Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation.
    Esteves-Villanueva JO; Trzeciakiewicz H; Loeffler DA; Martić S
    Biochemistry; 2015 Jan; 54(2):293-302. PubMed ID: 25545358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific binding of intravenous immunoglobulin products to tau peptide fragments.
    Smith LM; Coffey MP; Loeffler DA
    Int Immunopharmacol; 2014 Aug; 21(2):279-82. PubMed ID: 24859060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein.
    Smith LM; Coffey MP; Klaver AC; Loeffler DA
    Int Immunopharmacol; 2013 Aug; 16(4):424-8. PubMed ID: 23669333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELISA measurement of specific antibodies to phosphorylated tau in intravenous immunoglobulin products.
    Loeffler DA; Klaver AC; Coffey MP
    Int Immunopharmacol; 2015 Oct; 28(2):1108-12. PubMed ID: 26330100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils.
    Marreiro A; Van Kolen K; Sousa C; Temmerman L; Vasconcelos B; Crespo-Rodriguez R; van Weering JRT; Van Dam D; De Deyn PP; Apetri A; Schoofs L; Mercken MH
    BMC Mol Cell Biol; 2020 Nov; 21(1):81. PubMed ID: 33183222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation.
    Tomoo K; Yao TM; Minoura K; Hiraoka S; Sumida M; Taniguchi T; Ishida T
    J Biochem; 2005 Oct; 138(4):413-23. PubMed ID: 16272135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser
    van Ameijde J; Crespo R; Janson R; Juraszek J; Siregar B; Verveen H; Sprengers I; Nahar T; Hoozemans JJ; Steinbacher S; Willems R; Delbroek L; Borgers M; Dockx K; Van Kolen K; Mercken M; Pascual G; Koudstaal W; Apetri A
    Acta Neuropathol Commun; 2018 Jul; 6(1):59. PubMed ID: 30001207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product.
    Hromadkova L; Kolarova M; Jankovicova B; Bartos A; Ricny J; Bilkova Z; Ripova D
    J Neuroimmunol; 2015 Dec; 289():121-9. PubMed ID: 26616881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation.
    Taniguchi T; Sumida M; Hiraoka S; Tomoo K; Kakehi T; Minoura K; Sugiyama S; Inaka K; Ishida T; Saito N; Tanaka C
    FEBS Lett; 2005 Feb; 579(6):1399-404. PubMed ID: 15733848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can any "non-specific charge modification within microtubule binding domains of Tau" be a prerequisite of the protein amyloid aggregation? An in vitro study on the 1N4R isoform.
    Jangholi A; Ashrafi-Kooshk MR; Arab SS; Karima S; Poorebrahim M; Ghadami SA; Moosavi-Movahedi AA; Khodarahmi R
    Int J Biol Macromol; 2018 Apr; 109():188-204. PubMed ID: 29248553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin Inhibits Tau Aggregation and Disintegrates Preformed Tau Filaments in vitro.
    Rane JS; Bhaumik P; Panda D
    J Alzheimers Dis; 2017; 60(3):999-1014. PubMed ID: 28984591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
    Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
    J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based inhibitors of tau aggregation.
    Seidler PM; Boyer DR; Rodriguez JA; Sawaya MR; Cascio D; Murray K; Gonen T; Eisenberg DS
    Nat Chem; 2018 Feb; 10(2):170-176. PubMed ID: 29359764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer disease hyperphosphorylated tau aggregates hydrophobically.
    Ruben GC; Ciardelli TL; Grundke-Iqbal I; Iqbal K
    Synapse; 1997 Nov; 27(3):208-29. PubMed ID: 9329157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry.
    Huang RY; Iacob RE; Sankaranarayanan S; Yang L; Ahlijanian M; Tao L; Tymiak AA; Chen G
    J Am Soc Mass Spectrom; 2018 Jan; 29(1):174-182. PubMed ID: 28971440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain.
    Barghorn S; Davies P; Mandelkow E
    Biochemistry; 2004 Feb; 43(6):1694-703. PubMed ID: 14769047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy.
    Sibille N; Sillen A; Leroy A; Wieruszeski JM; Mulloy B; Landrieu I; Lippens G
    Biochemistry; 2006 Oct; 45(41):12560-72. PubMed ID: 17029411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural study of the recognition mechanism of tau antibody Tau2r3 with the key sequence (VQIINK) in tau aggregation.
    Tsuchida T; Susa K; Kibiki T; Tsuchiya T; Miyamoto K; In Y; Minoura K; Taniguchi T; Ishida T; Tomoo K
    Biochem Biophys Res Commun; 2021 Dec; 585():36-41. PubMed ID: 34784549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
    Klaver AC; Coffey MP; Smith LM; Loeffler DA
    Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
    Harrington CR; Storey JM; Clunas S; Harrington KA; Horsley D; Ishaq A; Kemp SJ; Larch CP; Marshall C; Nicoll SL; Rickard JE; Simpson M; Sinclair JP; Storey LJ; Wischik CM
    J Biol Chem; 2015 Apr; 290(17):10862-75. PubMed ID: 25759392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.